glp 1 agonist alternative equivalency chart Promising New Science on Weight Loss Drug Alternatives Indications for GLP-1/GIP RA Summary

[DOI] [PubMed] [Google Scholar] 104

2033 (USD BILLION) FIGURE 13 GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2025 VS

Mazdutide (IBI362): The Next-Generation Dual GLP-1/Glucagon Agonist for Obesity and Metabolic Health Abstract Mazdutide (IBI362) is an emerging dual GLP-1 and glucagon receptor agonist developed by Innovent Biologics for obesity and metabolic diseases

The global oral thrombopoietin receptor agonists market was estimated at US$ 4.73 billion in 2023 and is projected to grow to US$ 9.95 billion by 2034, rising at a compound annual growth rate (CAGR) of 7% from 2024 to 2034

14 BrownEHeerspinkHJLCuthbertsonDJWildingJPH